psychedelic compound MEAI

Clearmind Medicine Inc. (NASDAQ: CMND), an Israeli biotech company received approval from the IMCA center’s Ethics Committee for the announced Phase 1/2 clinical trial assessing its proprietary MEAI-based compound, CMND-100, for the treatment of Alcohol Use Disorder (AUD.) Clearmind ...

Alcohol Use Disorder (AUD) is one of the top-targeted health issues by biopharma companies. In the case of Clearmind Medicine (NASDAQ: CMND), the Israel-based company is going at it through its MEAI-based proprietary drug candidate, CMND-100. After the novel compound’s positive...

Monash University Engages LaNeo MDMA Australian Monash University’s psychedelics research lab has contracted MDXX-class molecules developer PharmAla Biotech to manufacture and supply its clinical-grade MDMA LaNeo for an upcoming Phase 2 clinical study. Delivery is set for this summer. This is...

Israeli biotech Clearmind Medicine Inc. (NASDAQ: CMND) has submitted an Investigational New Drug (IND) application with the FDA towards approval to commence its first-in-human Phase 1/2a clinical trial with MEAI-based CMND-100 in patients diagnosed with Alcohol Use Disorder (AUD).  The active...

(Part four of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains Next-Generation Psychedelics, MEAI - What And When Clearmind...

(Part three of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains MEAI is a potent synthetic molecule essentially developed in the...

(This is part two of a four-part series) Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction A compound developed by Israeli psychedelics company Clearmind Medicine (NASDAQ: CMND) would act by providing a similar feeling to...

(Part one of a four-part series) Increasing evidence of psychedelics’ potential for benefiting both mental and physical health conditions are moving biotech companies and scientists in the sector to major innovative heights. Psychedelic science is growing in terms of treatment specificity, as...

Israeli-Canadian biotech psychedelics developer Clearmind Medicine Inc. (OTC Pink: CMNDF) together with clinical-stage cannabinoid pharma company SciSparc Ltd. (NASDAQ: SPRC) announced that their collaborative study of cocaine addiction treatment with the non-hallucinogenic psychedelic compound...